Brokerages expect that Aptevo Therapeutics Inc (NASDAQ:APVO) will post earnings per share (EPS) of ($0.76) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aptevo Therapeutics’ earnings. Aptevo Therapeutics reported earnings per share of ($0.48) in the same quarter last year, which indicates a negative year-over-year growth rate of 58.3%. The company is expected to issue its next earnings report on Friday, May 11th.
On average, analysts expect that Aptevo Therapeutics will report full-year earnings of ($3.29) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of ($2.87) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Aptevo Therapeutics.
NASDAQ:APVO opened at $3.17 on Friday. The stock has a market cap of $72.42, a price-to-earnings ratio of -2.07 and a beta of 0.68. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.14 and a quick ratio of 5.08. Aptevo Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $4.85.
A number of large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in Aptevo Therapeutics by 411.8% during the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock valued at $1,816,000 after purchasing an additional 344,700 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Aptevo Therapeutics during the 4th quarter valued at about $827,000. Virtu Financial LLC bought a new stake in Aptevo Therapeutics during the 4th quarter valued at about $690,000. Finally, Acadian Asset Management LLC increased its stake in Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 31,578 shares in the last quarter. Institutional investors and hedge funds own 33.04% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3337395/aptevo-therapeutics-inc-apvo-expected-to-post-earnings-of-0-76-per-share.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.